Answers are grounded in this paper and cite their sources.
Background/Objectives: Automated phlebotomy may improve preanalytical quality and access to venous blood testing. Prior work evaluating the Aletta Autonomous Robotic Phlebotomy Device (ARPD) demonstrated analytical equivalence. This study expanded the initial analytical validation to additional blood collection tubes and analytes and also assessed real-world hemolysis rates. Methods: The study was conducted in three hospital outpatient phlebotomy departments, including a site with a high prevalence of (hemato-)oncology patients. The within-subject analytical validation study included Greiner VACUETTE (Cohort 1) and BD Vacutainer (Cohort 2) serum, lithium heparin, and EDTA tubes. Equivalence of potassium, lactate dehydrogenase, hemolysis index, and complete blood count (CBC) with differential between paired ARPD-collected and manually collected samples was assessed using Passing–Bablok regression. Real-world ARPD hemolysis (>0.5 g/L free hemoglobin) rates were determined in a separate cohort (Cohort 3) and compared with site-specific manual hemolysis rates. Results: In the analytical validation study, 119 patients were included in the analysis (Cohort 1, n = 52; Cohort 2, n = 67). All tests met the predefined acceptability criteria. The hemolysis index was statistically significantly lower in ARPD-collected lithium heparin samples in Cohort 1. In real-world use (1368 ARPD venipunctures), the ARPD hemolysis rate was 0.0% (95% CI: 0.0–0.3%), significantly lower than manual phlebotomy (1.6%, p = 0.025). Conclusions: The study demonstrated analytical equivalence in a clinically complex population and found reduced ARPD hemolysis rates. The results further substantiate that the ARPD could improve patient care by reducing preanalytical errors.
No takes yet. Share an insight, caveat, or question.
Roest et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: